Sentynl buys treatment for rare ageing disease


Biopharmaceutical company Sentynl Therapeutics has acquired Eiger Biopharmaceuticals’ approved treatment for the rare disease progeria.

Progeria, also known as Hutchinson-Gilford progeria syndrome (HGPS) and processing-deficient progeroid laminopathies (PDPL), in young people 12 months of age and older, are ultra-rare, fatal, genetic premature ageing diseases that accelerate mortality in young patients.

Eiger’s treatment Zokinvy targets the cause and symptoms of progeria. The treatment was first approved by the FDA in 2020 and then secured approval in the European Union and Great Britain in 2022, and in Japan this year.

The acquisition follows news that Eiger and its subsidiaries had filed for bankruptcy in April this year. Sentynl won a bidding auction for Zokinvy, claiming the therapy for a net price of $45.2 million, subject to certain purchase price adjustments. Under the terms of the acquisition, Sentynl acquired global rights to Zokinvy and will be responsible for its manufacture and commercialisation.

“It is an honour to add Zokinvy to our portfolio of products that have a tangible impact on the lives of rare disease patients, whose needs are too often unmet or overlooked,” said Matt Heck, President & Chief Executive Officer of Sentynl. “We are firmly committed to provide best-in-class global access to Zokinvy and are eager to serve the patients and their families affected by progeria. We are grateful to Eiger and The Progeria Research Foundation for their dedicated effort to develop and secure availability of this life-changing product.”

“We are pleased to complete this agreement with Sentynl, given our shared commitment to supporting patients of life-threatening, rare conditions with high unmet medical needs,” said David Apelian, CEO of Eiger. “We thank The Progeria Research Foundation for their continued support of Zokinvy.”

Audrey Gordon, President and Executive Director of The Progeria Research Foundation (PRF), added, “Without Zokinvy therapy, children with progeria die of the same heart disease that affects millions of normally ageing adults, but by an average age of 14.5 years old. Zokinvy gives these beautiful children longer, healthier lives. Since we first launched PRF in 1999, we have achieved tremendous progress in global awareness, breakthrough research, and treatment of progeria. We are thankful for our successful partnership with Eiger, and are excited to now join forces with Sentynl in our journey to continue advancing the research and treatment of this syndrome, with the ultimate goal to find the cure.”

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free